It was a pleasure to speak with Dr Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the JADE REGIMEN Phase 3 trial (NCT03627767) investigating abrocitinib in patients with atopic dermatitis.
The abstract entitled ‘Abrocitinib Induction, Randomized Withdrawal and Response Recapture With Rescue Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE REGIMEN Phase 3 Trial’ was presented at AAD VMX, 23-25 April 2021.
- What is the rationale for the use of abrocitinib in the treatment of adults with moderate to severe atopic dermatitis? (0:14)
- Could you tell us about the unique design of the JADE REGIMEN Phase 3 study? (0:55)
- What was the response to abrocitinib in the induction, maintenance and rescue periods? (3:09)
- What was the safety profile of abrocitinib, and how can adverse events be minimized? (4:52)
- What are the significance of these findings in terms of the evolving treatment paradigm for atopic dermatitis? (6:18)
Disclosures: Dr. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Gil Yosipovitch, EADV 2022: Lebrikizumab Monotherapy for Moderate to Severe Atopic Dermatitis
ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967) are phase 3, randomised, double-blind, placebo-controlled trials, investigating lebrikizumab monotherapy in moderate to severe atopic dermatitis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) around the ADvocate 1 and ADvocate 2 phase 3 studies and the findings from his […]
Laura Carucci, EAACI 2022: Probiotic L.rhamnosus GG in Paediatric Atopic Dermatitis – Findings from the ProPAD Study
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the aims, outcome measures and findings from the ProPAD study, investigating L.rhamnosus GG in paediatric atopic dermatitis. The abstract […]
Laura Carucci, EAACI 2022: Health Burden of Paediatric Atopic Dermatitis and Impact of Probiotic Treatment
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the health burden of paediatric atopic dermatitis, the unmet needs in treatment and the potential of probiotic treatment. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!